arrow
S

Serena Ricciardi

san camillo/forlanini hospital
H指数:21
被引数:1,599

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Braf-mutant metastatic non-small-cell lung cancer: Real world data from the Italian biomarker atlas database

Braf突变转移性非小细胞肺癌: 来自意大利生物标志物图谱数据库的真实世界数据

2026-01-210
OAAI
Advanced-stage ALK-positive non–small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database

晚期ALK阳性非小细胞肺癌(NSCLC)患者:来自意大利生物标志物ATLAS数据库的真实世界治疗模式与结果

2025-09-240
OAAI
A prospective study on clinicians' attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020)

一项关于免疫治疗时代下,临床医生对晚期非小细胞肺癌(NSCLC)及体力状态较差患者的态度与生存结局的前瞻性研究:PICASO(GOIRC-04-2020)。

2025-06-010
PRE
Advanced ALK-positive non-small cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database

晚期ALK阳性非小细胞肺癌(NSCLC)患者:来自意大利生物标志物ATLAS数据库的真实世界治疗模式与结果

2024-09-010
PRE
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours

肝细胞癌患者与其他晚期实体瘤患者免疫治疗相关肝损伤的特征和结局

2024-03-0111
OA
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma compared to patients with advanced solid tumours
2024-02-010
PRE
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study
2023-07-013
OAAI
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status
2022-01-215
OAAI
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy

基于药物的评分对接受一线免疫治疗的晚期非小细胞肺癌患者的预测能力

2021-06-0124
OAAI
Post-progression outcomes of NSCLC patients with PD-L1 expression > 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study

在一项大型多中心真实世界研究中接受一线单药pembrolizumab治疗的PD-L1表达> 50% 的NSCLC患者的进展后结局

2021-05-0120
OAAI
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

抗生素治疗和其他药物对一线pembrolizumab与细胞毒性化疗治疗的非小细胞肺癌患者肿瘤学结局的差异影响

2021-04-0797
OAAI
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes

在PD-L1表达 ≥ 50% 的NSCLC患者的大型真实队列中,派姆单抗的免疫相关不良事件及其与临床结局的关系

2020-11-0163
OAAI
Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer
2019-12-0153
PREAI
Activity of the EGFR-HER2 Dual Inhibitor Afatinib in EGFR-Mutant Lung Cancer Patients With Acquired Resistance to Reversible EGFR Tyrosine Kinase Inhibitors

EGFR-HER2双重抑制剂阿法替尼在可逆性EGFR酪氨酸激酶抑制剂获得性耐药的EGFR突变型肺癌患者中的活性

2014-11-0134
OAAI